Innovent Biologics (01801) saw its shares climb nearly 3%, reaching an increase of 2.2% to HK$83.6 by the time of writing, with a trading volume of HK$204 million. According to an announcement on the company's official WeChat account dated January 27, 2026, its anti-GPRC5D/BCMA/CD3 trispecific antibody, IBI3003, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). The intended indication is for the treatment of relapsed or refractory multiple myeloma (R/R MM) in patients who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody. IBI3003 was developed using Innovent Biologics' proprietary Sanbody® platform and is currently undergoing Phase I/II clinical studies in China, Australia, and the United States (initiation imminent) to evaluate its efficacy and safety in R/R MM.